Here, we describe severe neuropsychiatric symptoms in an HIV-positive Asian man with extremely high efavirenz plasma levels while receiving standard treatment with efavirenz/tenofovir/emtricitabine fixed-dose regimen. Genetic examination revealed compound homozygosity for loss-of-function alleles of CYP2B6, including coding for a rare truncated protein. Neuropsychiatric symptoms resolved completely after efavirenz discontinuation.
References
1.
ThompsonM.A.A.J., HoyJ.F., TelentiA.Antiretroviral treatment of adult HIV infection: 2012 recommendations of the international antiviral society–USA panel. JAMA2012; 308: 387–402.
SarahC Sim. The human cytochrome P450 (CYP) allele nomenclature database. (Updated 11 February 2013. Accessed 17 July 2013.) Available from http://www.cypalleles.ki.se/index.htm.
4.
von RichterO., PitarqueM., Rodríguez-AntonaC.Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). Pharmacogenetics2004; 14: 369–379.
5.
LubomirovR., ColomboS., di IulioJ.Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis2011; 203: 246–257.
6.
ColomboS., BeguinA., TelentiA.Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci2005; 819: 259–276.
7.
CusiniA., VernazzaP.L., YerlyS.Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr2013; 62: 28–35.
8.
Stichting Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie [Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology]. (Updated 31 December 2012. Accessed 15 February 2013.) Available from www.kkgt.nl.
9.
YilmazA., WatsonV., DickinsonL., BackD.Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. Antimicrob Agents Chemother2012; 56: 4583–4585.
10.
BestB.M., KoopmansP.P., LetendreS.L.Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother2011; 66: 354–357.
11.
TashimaK.T., CaliendoA.M., AhmadM.Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis1999; 180: 862–864.
12.
GutmannC., CusiniA., GunthardH.F.Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS2010; 24: 2347–2354.
13.
GazzardB.G.Efavirenz in the management of HIV infection. Int J Clin Pract1999; 53: 60–64.
14.
PuzantianT.Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy2002; 22: 930–933.
15.
GutiérrezF., NavarroA., PadillaS.Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis2005; 41: 1648–1653.
16.
RuizN.M.B.L., ManionD.J.Potential adverse experiences associated with EFV in adults.6th Conference on Retroviruses and Opportunistic Infections. 31 January–4 February 1999, Chicago, IL, USA. Abstract 655.
17.
PeyriereH., MauboussinJ-M, RouanetI., FabreJ., ReynesJ., Hillaire-BuysD.Management of sudden psychiatric disorders related to efavirenz. AIDS2001; 15: 1323–1324.
18.
MarzoliniC., TelentiA., DecosterdL.A., GreubG., BiollazJ., BuclinT.Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS2001; 15: 71–75.
19.
HasseB., GünthardH.F., BleiberG., KrauseM.Efavirenz Intoxication Due to Slow Hepatic Metabolism. Clin Infect Dis2005; 40: e22–e23.
20.
WardB.A., GorskiJ.C., JonesD.R., HallS.D., FlockhartD.A., DestaZ.The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther2003; 306: 287–300.
21.
Di IulioJ., FayetA., Arab-AlameddineM.In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics2009; 19: 300–309.
22.
RotgerM., ColomboS., FurrerH.Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics2005; 15: 1–5.
23.
HaasD.W., RibaudoH.J., KimR.B.Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS2004; 18: 2391–2400.
24.
TsuchiyaK., GatanagaH., TachikawaN.Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun2004; 319: 1322–1326.
RotgerM., TegudeH., ColomboS.Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther2007; 81: 557–566.
27.
ChungT.N., KimS.W., ParkY.S., ParkI.Unilateral blindness with third cranial nerve palsy and abnormal enhancement of extraocular muscles on magnetic resonance imaging of orbit after the ingestion of methanol. Emerg Med J2010; 27: 409–410.
28.
MacchiaioloM.V.E., GonfiantiniM.V., GrandinA.An unusual case of anisocoria by vegetal intoxication: a case report. Ital J Pediatr2010; 36: 50.
